VSTM
Verastem, Inc.
NASDAQ · USHealthcareBiotechnology
$5.75-4.64%
Price as of Jul 20, 2026
VSTM financials
Verastem, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $30.9M | $10.0M | $0.00 | $2.6M |
| Cost of revenue | $5.3M | $0.00 | $0.00 | $0.00 |
| Gross profit | $25.6M | $10.0M | $0.00 | $2.6M |
| Operating expenses | $195.7M | $125.0M | $92.1M | $75.5M |
| Operating income | -$170.1M | -$115.0M | -$92.1M | -$72.9M |
| Net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M |
| EBITDA | -$207.6M | -$125.9M | -$83.2M | -$71.6M |
| Basic EPS | $-3.02 | $-3.66 | $-3.96 | $-4.57 |
| Diluted EPS | $-3.02 | $-3.66 | $-3.96 | $-4.57 |
| Balance sheet | ||||
| Cash & equivalents | $205.0M | $88.8M | $77.9M | $74.9M |
| Total assets | $246.4M | $101.5M | $149.7M | $95.0M |
| Total liabilities | $189.2M | $130.4M | $92.3M | $47.7M |
| Stockholders’ equity | $57.2M | -$28.9M | $57.4M | $47.4M |
| Total debt | $76.9M | $42.3M | $41.6M | $27.1M |
| Net debt | -$128.1M | -$46.6M | -$36.4M | -$47.9M |
| Cash flow | ||||
| Operating cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M |
| Capital expenditure | $0.00 | -$28.0K | $0.00 | $0.00 |
| Free cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |